Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI(NASDAQ:KPTI) NEWTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 466 restricted stock units (RSUs) to two newly-hired employees....
KP Tissue declares a Quarterly Dividend of $0.18 per Common Share
KPTINOT FOR DISTRIBUTION IN THE U.S.A. OR OVER U.S. WIRE SERVICES
KP Tissue Releases Second Quarter 2025 Financial Results
KPTIStrong profitability with Memphis investment to drive efficiency and support growing U.S. business
Strong profitability with Memphis investment to drive efficiency and support growing U.S. business
Karyopharm Announces Poster Presentation On Selinexor In Myelofibrosis At The 2025 EHA Annual Meeting
KPTIThese Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
KPTIRBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $33
KPTIBarclays Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $10
KPTIBaird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $42
KPTIKaryopharm Therapeutics Affirms FY2025 Sales Guidance of $140.00M-$155.00M vs $149.32M Est
KPTIKaryopharm Therapeutics Q1 EPS $(2.77) Beats $(4.16) Estimate, Sales $30.02M Miss $35.24M Estimate
KPTIBaird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $54
KPTITrading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
KPTIHC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $56
KPTITrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
KPTIKaryopharm Therapeutics shares are trading lower after the company announced a 1-for-15 reverse stock split.
KPTIKaryopharm Announces 1-for-15 Reverse Stock Split, Effective February 25, 2025
KPTIRBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target
KPTIHC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
KPTIKaryopharm Says Phase 3 XPORT-EC-042 Trial Of Selinexor As Maintenance Therapy In Advanced or Recurrent TP53 Wild-Type Endometrial Cancer To Focus Enrollment Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for C
KPTIKaryopharm Expects 2025 Sales Of $140M-$155M Versus Consensus Of $160.55M, With US Xpovio Net Product Revenue Expected To Be $115M-$130M
KPTIKaryopharm Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Sales $30.54M Miss $34.86M Estimate
KPTIHC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
KPTIKaryopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Naïve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales Reached $
KPTIPiper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5
KPTIHC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
KPTIKaryopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M
KPTIKaryopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate
KPTIHC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
KPTIKaryopharm Therapeutics Announced That, Following FDA Feedback, The Company Will Be Replacing TSS50, One Of The Co-primary Endpoints In The Phase 3 SENTRY Trial With Abs-TSS
KPTIExpert Ratings for Karyopharm Therapeutics
KPTIAnalysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter:
Where Karyopharm Therapeutics Stands With Analysts
KPTIKaryopharm Therapeutics (NASDAQ:KPTI) has observed the following analyst ratings within the last quarter:
Morgan Stanley Maintains Equal-Weight on Karyopharm Therapeutics, Lowers Price Target to $7
KPTIKaryopharm Therapeutics Earnings Preview
KPTIKaryopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Karyopharm Therapeutics will report an earnings per share (EPS) of $-0.63.
